Abstract
AbstractIn this study suitability of α-ZrP nanoparticles as a 223Ra and 225Ac carriers for TAT was investigated. The yields of radiolabelling were higher than 98% in both cases. Subsequently, in vitro stability studies were carried out in various biological matrices during 48 h period. Measurements of released radioactivity showed the highest stability in saline. Released activity of 223Ra, 225Ac and their daughter radionuclides was around 0.5%. On the other hand, the lowest stability was shown in plasma and serum. Released activity for 223Ra, 225Ac and their progeny atoms was from 15 to 32%.
Funder
Technology Agency of the Czech Republic
České Vysoké Učení Technické v Praze
Czech Technical University in Prague
Publisher
Springer Science and Business Media LLC
Subject
Health, Toxicology and Mutagenesis,Public Health, Environmental and Occupational Health,Spectroscopy,Pollution,Radiology, Nuclear Medicine and imaging,Nuclear Energy and Engineering,Analytical Chemistry
Reference22 articles.
1. Morgenstern A, Apostolidis C, Kratochwil C, Sathekge M, Krolicki L, Bruchertseifer F (2018) An overview of targeted alpha therapy with 225actinium and 213bismuth. Curr Radiopharm 11:200–208
2. Guerra Liberal FDC, O’Sullivan JM, McMahon SJ, Prise KM (2020) Targeted alpha therapy: current clinical applications. Cancer Biother Radiopharm 35:404–417
3. Kim YS, Brechbiel MW (2012) An overview of targeted alpha therapy. Tumour Biol 33:573–590
4. Kozempel J, Mokhodoeva O, Vlk M (2018) Progress in targeted alpha-particle therapy: what we learned about recoils release from in vivo generators. Molecules 23:581
5. Majkowska-Pilip A, Gawęda W, Żelechowska-Matysiak K, Wawrowicz K, Bilewicz A (2020) Nanoparticles in targeted alpha therapy. Nanomaterials 10:1366
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献